Clearside Biomedical, Inc. appointed David S. Boyer, David M. Brown, Nancy M. Holekamp, Peter K. Kaiser and Carl D. Regillo as Scientific Advisory Board. David S. Boyer, M.D. is a clinician, surgeon, and educator at the Retina-Vitreous Associates Medical Group in Southern California. He is board certified in ophthalmology and has completed formal sub-specialty training in medical and surgical diseases of the retina, vitreous, and macula. Dr. Boyer is currently a leading investigator for various national clinical trials on retinal diseases and serves as an advisor for multiple research, educational and charitable institutions. He received his medical degree from the Chicago Medical School, finished his residency at the Los Angeles County - USC County Medical Center, and completed his retinal surgery fellowship at the Wills Eye Hospital in Philadelphia. David M. Brown, M.D. is a medical and surgical retinal specialist and clinical trial specialist at Retina Consultants Houston. He has pioneered research in the areas of age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion. He is the director of the Greater Houston Retina Research Center, a clinical professor of Ophthalmology at Baylor College of Medicine, the Vice-Chair for research at the Blanton Eye Institute at Houston Methodist Hospital, and serves as the consultant retinal specialist for NASA. Dr. Brown received his medical degree from Baylor College of Medicine, and completed ophthalmology and retina training at the University of Iowa. Nancy M. Holekamp, M.D. is a professor of Clinical Ophthalmology and Visual Sciences at the Washington University School of Medicine, and director of Retina Services at the Pepose Vision Institute, both in St. Louis, Missouri. She has been actively involved in clinical trials dealing with AMD, retinal vascular occlusion, and diabetic retinopathy. Dr. Holekamp serves as a reviewer for multiple major ophthalmology journals, and served on the American Academy of Ophthalmology Ethics Committee for six years. Peter K. Kaiser, M.D. is the Chaney Family Endowed Chair for Ophthalmology Research and a Professor of Ophthalmology at the Cleveland Clinic Lerner College of Medicine. As an NIH grant funded investigator, Dr. Kaiser leads a team involved in the evaluation of vascular biology in AMD and diabetic retinopathy, and is actively involved in numerous clinical trials. He is Editor-in-Chief of Retinal Physician, Associate Editor of International Ophthalmology Clinics, and serves on the editorial boards of several other publications. Dr. Kaiser received his medical degree from Harvard Medical School, completed his internal medicine internship at Massachusetts General Hospital, an ophthalmology residency at the Massachusetts Eye and Ear Infirmary, and a vitreoretinal fellowship at Bascom Palmer Eye Institute. Carl D. Regillo, M.D., F.A.C.S is the Director of the Retina Service of Wills Eye Hospital, and Professor of Ophthalmology at Thomas Jefferson University School of Medicine. He is the principal investigator of numerous international clinical trials investigating new forms of treatment for macular degeneration, diabetic retinopathy, and other retinal conditions. Dr. Regillo is a fellow of the American College of Surgeons and has served on the scientific editorial board for several ophthalmic publications. He received his medical degree from Harvard Medical School and performed his internship in internal medicine at Harvard’s Brigham and Women’s Hospital in Boston, and both his ophthalmology residency and vitreoretinal fellowship at Wills Eye Hospital in Philadelphia. After training, he was commissioned as a Major in the United States Air Force and served four years as a vitreoretinal surgeon at the San Diego Naval Medical Center.
Clearside Biomedical, Inc. is a biopharmaceutical company focused on the delivery of therapies to the back of the eye through the suprachoroidal space (SCS). The Company's SCS injection platform, utilizing its patented SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. The Company is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector. The Company's lead program, CLS-AX (axitinib injectable suspension), for the treatment of neovascular age-related macular degeneration (wet AMD), is in Phase 2b clinical testing. It developed and gained approval for its product, XIPERE (triamcinolone acetonide injectable suspension) for suprachoroidal use, which is available in the United States through a commercial partner.